Syntis Bio, Inc.

Leann Quertinmont Teadt

Kristen Jean Vallieu

Kerryn McCluskie

Gjalt W Huisman

Vesna Mitchell

Nikki Dellas

Stephan Jenne

Joyce Liu

Stephanie Sue Galanie

Nikki D Kruse

Faye Loan Du

Kierra Aleece Franklin

The present invention provides engineered leucine decarboxylase (LDC) polypeptides and compositions thereof, as well as polynucleotides encoding the engineered leucine decarboxylase (LDC) polypeptides. In some embodiments, the engineered LDC polypeptides are optimized to provide enhanced catalytic activity, as well as reduced sensitivity to proteolysis, and/or increased tolerance to low pH environments. In some embodiments, the engineered LDC polypeptides are optimized to provide improved storage stability. The present invention also provides methods for the use of the compositions comprising the engineered LDC polypeptides for therapeutic and industrial purposes.

Engineered leucine decarboxylases

The present invention provides engineered methionine gamma lyase polypeptides and compositions thereof. The engineered methionine gamma lyase polypeptides have been optimized to provide improved thermostability, protease stability, and stability under a range of pH conditions, including acidic (pH<7) conditions. The present invention also relates to the use of the compositions comprising the engineered methionine gamma lyase polypeptides for therapeutic purposes.

Engineered methionine gamma lyase variants

Growing community of inventors

Redwood City, CA, United States of America

Leann Quertinmont Teadt